Loading organizations...
§ Private Profile · Shenzhen, Guangdong, China
Develops exosome purification products and early cancer detection technology for biotechnology applications.
Huixin Bio develops exosome purification products and early cancer detection technology, offering a world-leading platform for exosomal purification, diagnosis, and biomaterial generation. The biotechnology organization is currently in its pre-Series A stage, concentrating its efforts on advancing exosome-based solutions for various applications within the research, diagnostics, and biomaterial sectors. Their proprietary platform is designed to facilitate the isolation and analysis of exosomes, which hold significant promise for non-invasive diagnostics and therapeutic development across a broad range of medical conditions. While specific funding amounts or valuation figures are not publicly disclosed, the company is positioned within a rapidly evolving area of biotechnology, addressing a growing market need for advanced diagnostic tools. Guicheng Huixin has been identified as an investor with interests in related biotechnology ventures. Information regarding the company's founding year and specific founders is not publicly available.
Huixin Bio has raised $14.4M across 1 funding round.
Huixin Bio employs advanced methods for exosome purification, including a novel approach based on ultrasonic nanofiltration.
In addition to exosome purification products, Huixin Bio also researches and develops liquid biopsy diagnostic products.
Huixin Bio employs advanced methods for exosome purification, including a novel approach based on ultrasonic nanofiltration.
In addition to exosome purification products, Huixin Bio also researches and develops liquid biopsy diagnostic products.
Huixin Bio has raised $14.4M across 1 funding round. Most recently, it raised $14.4M Series A in February 2026.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Feb 9, 2026 | $14.4M Series A | Legend Capital | — | Announced |
Huixin Bio is a high-tech enterprise that was established by renowned scientists and industry experts in the field of exosomes. The company's core mission is to drive the research and application of exosome technology, with a significant focus on its potential in early cancer diagnosis and treatment.
The company's product portfolio includes specialized exosome purification products. These solutions leverage advanced methodologies, such as ultrasonic nanofiltration, to provide efficient and effective exosome isolation for various research and diagnostic purposes.
Beyond purification, Huixin Bio is actively engaged in the research and development of liquid biopsy diagnostic products. Their overarching goal is to develop world-leading biomedical technologies and products that address critical needs within the healthcare sector.
Founded in 2017, Huixin Bio is headquartered in Shenzhen, Guangdong, China, operating as a private entity within the biopharmaceutical industry. The company contributes to the regional biotech ecosystem through its specialized focus.
Their involvement in scientific gatherings, such as the ISEV 2023 conference, underscores their engagement with the broader scientific community. At such events, discussions around extracellular vesicles (EVs) in diagnostics and therapeutics are central, and Huixin Bio's product, EXODUS, has been noted.